… II study of erlotinib, found that the development of skin rash, … analysis of serum samples
from patients with solid tumors … molecular responses to erlotinib in head and neck cancer. Clin …

… The worst grade of skin toxicities was significantly correlated … in 42 patients with head and
neck squamous carcinoma [4]. … between erlotinib pharmacokinetics and pharmacodynamics …

… combination with erlotinib was well tolerated with four patients (… 1 evaluation in patients with
advanced cancers including … pharmacokinetics, pharmacodynamics, and anti-cancer activity …

… inversely correlated with tumor size post-erlotinib treatment, … of clinical responses to erlotinib
in HNSCC patients 62 . Overall, … Recent bioinformatic analysis of HNSCC patient tumors …

… to the Response Evaluation Criteria in Solid Tumors (RECIST); … study assessing low-dose
erlotinib in elderly or frail patients … metabolism affect pharmacodynamics and pharmacokinetics…

… This analysis involved patients … severe skin rash in patients exhibiting higher erlotinib
exposure or trough concentrations, suggesting evidence of a pharmacokinetic–pharmacodynamic …

… We recommended a pharmacokinetic evaluation to be … pharmacokinetics and
pharmacodynamics of erlotinib, 7 and … observed between plasma erlotinib concentrations and skin …

… Head and neck cancer is a heterogenous group of tumors, … of dasatinib with erlotinib in
patients with operable stage II-… However, in-depth analysis using the omics platforms would help …

… phase II studies with erlotinib. This study nicely illustrates that early evaluation of multiple
potential … , access to patient tissue or tumor samples to assess changes in the molecular profile, …

… To investigate the requirements for inducing EMT processes during NGF-induced erlotinib
resistance, we assessed whether genetic inhibition of Twist1 or Slug in HNSCC cells would …